Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

Abstract

The economic evaluation indicates that sorafenib is cost-effective as compared to BSC in HCC. Limitations include multiple data sources, use of expert opinion for resource use, and the lack of utility data.